唑来膦酸预防乳腺癌骨转移的疗效研究

目的 探讨唑来膦酸预防乳腺癌骨转移的疗效。方法 回顾性收集2006年1月至2009年12月期间新疆医科大学第一附属医院确诊的418例浸润性乳腺导管癌患者，根据患者用药情况将其分为2组：预防组216例，接受唑来膦酸预防治疗；对照组202例，未接受唑来膦酸预防治疗。比较2组患者的骨转移及复发情况。结果 预防组患者发生骨转移37例（17.13%），对照组发生骨转移73例（36.14%），预防组的骨转移发生率较低（χ 2=19.45，P＜0.05）；不同分子分型乳腺癌患者中，均是预防组的骨转移发生率低于对照组（P＜0.05）。2组患者的肺转移、肝转移、其他部位转移和多脏器转移发生率，以及复发率比较差异均无统计学意义（P＞0.05）。结论 乳腺癌术后化疗后给予唑来膦酸预防治疗具有显著的临床获益，可减少乳腺癌骨转移的发生。

Clinical Study on The Preventive Effect of Zoledronic Acid on The Bone Metastasis in Breast Cancer

Objective To study the preventive effect of zoledronic acid on the bone metastases of breast cancer. Methods Four hundred and eighteen female patients with infiltrating ductal carcinoma who were underwent surgery in The First Affiliated Hospital of Xinjiang Medical University from Jan. 2006 to Dec. 2009 were collected and divided into 2 group, patients of prevention group accepted the preventive remedy of zoledronic acid （n=216）, but patients of control group didn’t accept （n=202）. Comparison of incidence of bone metastases and recurrence was performed. Results There were 37 （17.13%） patients suffered bone metastases in prevention group and 73 （36.14%） patients in control group,so the incidence of bone metastases was higher in control group （χ2=19.45, P〈0.05）. But there were no significant difference on incidence of pulmonary metastasis, liver metastases, other parts of metastases, multiple organ metastases,and recurrence （P〉0.05）. Conclusion Zoledronic acid could significantly reduce the incidence of bone metastases for patients with breast cancer, who underwent chemotherapy of conventional dose after operation, and it can effectively improve the prognosis of patients with breast cancer.